T cells are key mediators of protection against infection. In particular, cytotoxic (CD8+) T cells provide immunity against intracellular infections such as viruses or malaria parasites in the liver. Harnessing T cell immunity through vaccination is therefore a highly desirable strategy to maximise the efficacy of next generation vaccines. The recent advances of messenger RNA (mRNA) vaccines, delivered via lipid nanoparticles (LNPs), have revolutionised vaccinology by offering a versatile platform capable of inducing potent protection against infection, yet their ability to induce potent and durable T cell responses remains underexplored. To address this, we sought to extend understanding of the quantity and quality of CD8+ T cell responses induced by different commercially licensed mRNA-based therapeutics. To do this, we adoptively transferred naive T cell receptor (TCR) transgenic T cells specific for the model antigen chicken ovalbumin (OVA), termed OT-I T cells, into naive C57BL/6 recipient mice. Subsequently, we vaccinated these mice with the Moderna ‘Spikevax’, Pfizer-BioNTech ‘Comirnaty’ and Patisiran ‘Onpattro’ LNP’s containing mRNA encoding the OT-I T cell target OVA. The numbers and phenotype of OT-I cells in the liver and spleen across early effector, short-term and long-term memory timepoints were then examined, including a detailed comparison of the relative frequencies of central memory (TCM), effector memory (TEM) and tissue resident memory (TRM) T cells elicited. We reveal the induction of robust T cell responses by all these vaccines. These responses were conducive to the generation of abundant T cell memory, including TRM cells in the liver. Strategies to increase the numbers of these cells and their persistence were assessed. Our work offers valuable insight into the capacity of mRNA vaccines to induce CD8+ T cell responses and on their longevity, and will inform the development of mRNA vaccines that harness the protective capacity of T cells for improved efficacy.